{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:06:31Z","timestamp":1792073191392,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-024-02922-6","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:04:10Z","timestamp":1730739850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["MSC\u2013microvesicles protect cartilage from degradation in early rheumatoid arthritis via immunoregulation"],"prefix":"10.1186","volume":"22","author":[{"given":"Shixiong","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Juan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"2922_CR1","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591\u2013602.","journal-title":"Nat Rev Rheumatol"},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"1051082","DOI":"10.3389\/fimmu.2022.1051082","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: focus on pathogenesis and treatment. Front Immunol. 2022;13:1051082.","journal-title":"Front Immunol"},{"key":"2922_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13075-023-03009-7","volume":"25","author":"EC de Moel","year":"2023","unstructured":"de Moel EC, Trouw LA, Terao C, Govind N, Tikly M, El-Gabalawy H, et al. Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations. Arthritis Res Ther. 2023;25:37.","journal-title":"Arthritis Res Ther"},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51:vi5\u20139.","journal-title":"Rheumatology"},{"key":"2922_CR5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"2922_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA. 2018;320:1360.","journal-title":"JAMA"},{"key":"2922_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mcna.2020.10.006","volume":"105","author":"JJ Cush","year":"2021","unstructured":"Cush JJ. Rheumatoid arthritis. Med Clin N Am. 2021;105:355\u201365.","journal-title":"Med Clin N Am"},{"key":"2922_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0000000000000708","volume":"32","author":"HK Greenblatt","year":"2020","unstructured":"Greenblatt HK, Kim HA, Bettner LF, Deane KD. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol. 2020;32:289\u201396.","journal-title":"Curr Opin Rheumatol"},{"key":"2922_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00281-017-0620-6","volume":"39","author":"A Tracy","year":"2017","unstructured":"Tracy A, Buckley CD, Raza K. Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start? Semin Immunopathol. 2017;39:423\u201335.","journal-title":"Semin Immunopathol"},{"key":"2922_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clim.2018.05.004","volume":"195","author":"N Lingampalli","year":"2018","unstructured":"Lingampalli N, Sokolove J, Lahey LJ, Edison JD, Gilliland WR, Holers VM, et al. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis. Clin Immunol. 2018;195:119\u201326.","journal-title":"Clin Immunol"},{"key":"2922_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/art.40562","volume":"70","author":"MK Verheul","year":"2018","unstructured":"Verheul MK, B\u00f6hringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, et al. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis. Arthritis Rheumatol. 2018;70:1721\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"2922_CR13","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1002\/art.37686","volume":"64","author":"DB Bas","year":"2012","unstructured":"Bas DB, Su J, Sandor K, Agalave NM, Lundberg J, Codeluppi S, et al. Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheumatol. 2012;64:3886\u201396.","journal-title":"Arthritis Rheumatol"},{"key":"2922_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.23049","volume":"58","author":"KS Nandakumar","year":"2007","unstructured":"Nandakumar KS, Bajtner E, Hill L, B\u00f6hm B, Rowley MJ, Burkhardt H, et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheumatol. 2007;58:184\u201396.","journal-title":"Arthritis Rheumatol"},{"key":"2922_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.38273","volume":"66","author":"MJH de Hair","year":"2014","unstructured":"de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, Hansson M, Landew\u00e9 R, van der Leij C, et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 2014;66:513\u201322.","journal-title":"Arthritis Rheumatol"},{"key":"2922_CR16","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s00259-022-05836-3","volume":"49","author":"L Ge","year":"2022","unstructured":"Ge L, Fu Z, Wei Y, Shi D, Geng Y, Fan H, et al. Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2022;49:4025\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2922_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102923","volume":"133","author":"TA De Jong","year":"2022","unstructured":"De Jong TA, de Hair MJH, van de Sande MGH, Semmelink JF, Choi IY, Gerlag DM, et al. Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: a prospective study. J Autoimmun. 2022;133: 102923.","journal-title":"J Autoimmun"},{"key":"2922_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101438","volume":"33","author":"P Martins","year":"2019","unstructured":"Martins P, Fonseca JE. How to investigate: pre-clinical rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019;33: 101438.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2922_CR19","doi-asserted-by":"publisher","first-page":"R92","DOI":"10.1186\/ar4536","volume":"16","author":"HW van Steenbergen","year":"2014","unstructured":"van Steenbergen HW, van Nies JAB, Huizinga TWJ, Reijnierse M, van der Helm-Van Mil AHM. Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody-negative arthralgia patients at risk for rheumatoid arthritis. Arthritis Res Ther. 2014;16:R92.","journal-title":"Arthritis Res Ther"},{"key":"2922_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1546-0096-12-22","volume":"12","author":"L Berntson","year":"2014","unstructured":"Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, et al. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol. 2014;12:22.","journal-title":"Pediatr Rheumatol"},{"key":"2922_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3350\/cmh.2020.0194","volume":"27","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol. 2021;27:70\u201380.","journal-title":"Clin Mol Hepatol"},{"key":"2922_CR22","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/sctm.21-0021","volume":"10","author":"LT Wang","year":"2021","unstructured":"Wang LT, Liu KJ, Sytwu HK, Yen ML, Yen BL. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem cells Transl Med. 2021;10:1288\u2013303.","journal-title":"Stem cells Transl Med"},{"key":"2922_CR23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/ijms18091852","volume":"18","author":"FJ Vizoso","year":"2017","unstructured":"Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:1852.","journal-title":"Int J Mol Sci"},{"key":"2922_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2019.04.002","volume":"46","author":"P Kumar","year":"2019","unstructured":"Kumar P, Kandoi S, Misra R, Vijayalakshmi S, Rajagopal K, Verma RS. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2922_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749192","volume":"12","author":"Z Shen","year":"2021","unstructured":"Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol. 2021;12: 749192.","journal-title":"Front Immunol"},{"key":"2922_CR26","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3390\/ijms20153738","volume":"20","author":"FJ Vizoso","year":"2019","unstructured":"Vizoso FJ, Eiro N, Costa L, Esparza P, Landin M, Diaz-Rodriguez P, et al. Mesenchymal stem cells in homeostasis and systemic diseases: hypothesis, evidences, and therapeutic opportunities. Int J Mol Sci. 2019;20:3738.","journal-title":"Int J Mol Sci"},{"key":"2922_CR27","doi-asserted-by":"publisher","first-page":"16214","DOI":"10.1038\/s41598-017-15376-8","volume":"7","author":"S Cosenza","year":"2017","unstructured":"Cosenza S, Ruiz M, Toupet K, Jorgensen C, No\u00ebl D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep. 2017;7:16214.","journal-title":"Sci Rep"},{"key":"2922_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.716853","volume":"9","author":"M Najar","year":"2022","unstructured":"Najar M, Melki R, Khalife F, Lagneaux L, Bouhtit F, Moussa Agha D, et al. Therapeutic mesenchymal stem\/stromal cells: value, challenges and optimization. Front Cell Dev Biol. 2022;9: 716853.","journal-title":"Front Cell Dev Biol"},{"key":"2922_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cells9051145","volume":"9","author":"VK Mishra","year":"2020","unstructured":"Mishra VK, Shih HH, Parveen F, Lenzen D, Ito E, Chan TF, et al. Identifying the therapeutic significance of mesenchymal stem cells. Cells. 2020;9:1145.","journal-title":"Cells"},{"key":"2922_CR30","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","volume":"16","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge R, Anthony E, Barker RA, Bubela T, Brivanlou AH, Carpenter M, et al. ISSCR guidelines for stem cell research and clinical translation: the 2021 update. Stem Cell Rep. 2021;16:1398\u2013408.","journal-title":"Stem Cell Rep"},{"key":"2922_CR31","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1111\/cas.14563","volume":"111","author":"Z Xunian","year":"2020","unstructured":"Xunian Z, Kalluri R. Biology and therapeutic potential of mesenchymal stem cell-derived exosomes. Cancer Sci. 2020;111:3100\u201310.","journal-title":"Cancer Sci"},{"key":"2922_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","volume":"7","author":"Y Han","year":"2022","unstructured":"Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Sig Transduct Target Ther. 2022;7:92.","journal-title":"Sig Transduct Target Ther"},{"key":"2922_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41409-019-0616-z","volume":"54","author":"M Mendt","year":"2019","unstructured":"Mendt M, Rezvani K, Shpall E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant. 2019;54:789\u201392.","journal-title":"Bone Marrow Transplant"},{"key":"2922_CR34","doi-asserted-by":"publisher","first-page":"32570","DOI":"10.3402\/jev.v5.32570","volume":"5","author":"RA Haraszti","year":"2016","unstructured":"Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 2016;5:32570.","journal-title":"J Extracell Vesicles"},{"key":"2922_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis\u2014immune cell\u2013fibroblast\u2013bone interactions. Nat Rev Rheumatol. 2022;18:415\u201329.","journal-title":"Nat Rev Rheumatol"},{"key":"2922_CR36","first-page":"S249","volume":"16","author":"BH Resman-Targoff","year":"2010","unstructured":"Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care. 2010;16:S249\u201358.","journal-title":"Am J Manag Care"},{"key":"2922_CR37","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/eji.201646393","volume":"46","author":"TH Ramwadhdoebe","year":"2016","unstructured":"Ramwadhdoebe TH, H\u00e4hnlein J, Maijer KI, van Boven LJ, Gerlag DM, Tak PP, et al. Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis. Eur J Immunol. 2016;46:2812\u201321.","journal-title":"Eur J Immunol"},{"key":"2922_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE. 2012;7: e35296.","journal-title":"PLoS ONE"},{"key":"2922_CR39","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/ar3825","volume":"14","author":"M Mullazehi","year":"2012","unstructured":"Mullazehi M, Wick MC, Klareskog L, van Vollenhoven R, R\u00f6nnelid J. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res Ther. 2012;14:R100.","journal-title":"Arthritis Res Ther"},{"key":"2922_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.clinthera.2019.04.013","volume":"41","author":"K Raza","year":"2019","unstructured":"Raza K, Holers VM, Gerlag D. Nomenclature for the phases of the development of rheumatoid arthritis. Clin Ther. 2019;41:1279\u201385.","journal-title":"Clin Ther"},{"key":"2922_CR41","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2:1269\u201375.","journal-title":"Nat Protoc"},{"key":"2922_CR42","doi-asserted-by":"crossref","unstructured":"Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD. Collagen\u2010induced arthritis. Curr Protoc Immunol. 2010;89:15.5. 1\u201325.","DOI":"10.1002\/0471142735.im1505s89"},{"key":"2922_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.autrev.2007.08.001","volume":"7","author":"YG Cho","year":"2007","unstructured":"Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007;7:65\u201370.","journal-title":"Autoimmun Rev"},{"key":"2922_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","volume":"32","author":"D van der Woude","year":"2018","unstructured":"van der Woude D, van der Helm-Van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32:174\u201387.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2922_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.31138\/mjr.33.1.14","volume":"33","author":"P Sidiropoulos","year":"2022","unstructured":"Sidiropoulos P, Bounas A, Galanopoulos N, Vosvotekas G, Koukli EM, Georgiou P, et al. Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in rheumatoid arthritis patients in Greece: analysis of the Greek cohort of SENSE study. Mediterr J Rheumatol. 2022;33:14\u201334.","journal-title":"Mediterr J Rheumatol"},{"key":"2922_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.autrev.2019.05.007","volume":"18","author":"P Conigliaro","year":"2019","unstructured":"Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, et al. Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev. 2019;18:706\u201313.","journal-title":"Autoimmun Rev"},{"key":"2922_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113468","volume":"423","author":"B Harna","year":"2023","unstructured":"Harna B, Kalra P, Arya S, Jeyaraman N, Nallakumarasamy A, Jeyaraman M, et al. Mesenchymal stromal cell therapy for patients with rheumatoid arthritis. Exp Cell Res. 2023;423: 113468.","journal-title":"Exp Cell Res"},{"key":"2922_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13063-019-3403-7","volume":"20","author":"M Al-Laith","year":"2019","unstructured":"Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, et al. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019;20:429.","journal-title":"Trials"},{"key":"2922_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2019;78:179\u201385.","journal-title":"Ann Rheum Dis"},{"key":"2922_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/rheumatology\/kex386","volume":"57","author":"XM Teitsma","year":"2017","unstructured":"Teitsma XM, Jacobs JWG, Welsing PMJ, Peth\u00f6-Schramm A, Borm MEA, van Laar JM, et al. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology. 2017;57:309\u201317.","journal-title":"Rheumatology"},{"key":"2922_CR51","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","volume":"109","author":"M Ghoryani","year":"2019","unstructured":"Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran. Biomed Pharmacother. 2019;109:1834\u201340.","journal-title":"Biomed Pharmacother"},{"key":"2922_CR52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/vaccines11030687","volume":"11","author":"R Heydari","year":"2023","unstructured":"Heydari R, Koohi F, Rasouli M, Rezaei K, Abbasgholinejad E, Bekeschus S, et al. Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents. Vaccines. 2023;11:687.","journal-title":"Vaccines"},{"key":"2922_CR53","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/cells8080818","volume":"8","author":"D Tateiwa","year":"2019","unstructured":"Tateiwa D, Yoshikawa H, Kaito T. Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review. Cells. 2019;8:818.","journal-title":"Cells"},{"key":"2922_CR54","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/rheumatology\/keg327","volume":"42","author":"SR Goldring","year":"2003","unstructured":"Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology. 2003;42:ii11\u20136.","journal-title":"Rheumatology"},{"key":"2922_CR55","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/ijms21031071","volume":"21","author":"CC Tseng","year":"2020","unstructured":"Tseng CC, Chen YJ, Chang WA, Tsai WC, Ou TT, Wu CC, et al. Dual role of chondrocytes in rheumatoid arthritis: the chicken and the egg. Int J Mol Sci. 2020;21:1071.","journal-title":"Int J Mol Sci"},{"key":"2922_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","volume":"7","author":"M Kapoor","year":"2011","unstructured":"Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"2922_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/ncprheum0047","volume":"1","author":"U M\u00fcller-Ladner","year":"2005","unstructured":"M\u00fcller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Rev Rheumatol. 2005;1:102\u201310.","journal-title":"Nat Rev Rheumatol"},{"key":"2922_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/ncprheum0727","volume":"4","author":"G Murphy","year":"2008","unstructured":"Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol. 2008;4:128\u201335.","journal-title":"Nat Clin Pract Rheumatol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02922-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:09:00Z","timestamp":1730884140000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02922-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02922-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving MSC-MVs to protect cartilage from degradation in early rheumatoid arthritis via immunoregulation were approved by the Animal Research Committee of West China Hospital, Sichuan University (Approval Number: 2020285A, Date of Approval: September 22, 2020), and the Research Committee of West China Hospital, Sichuan University for human participants (Approval Number: 1771, Date: December 22, 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"673"}}